A 'low-tech' liposome ferried a generic chemo past the blood-brain barrier in mice after tumor surgery

Glioblastoma surgery briefly opens the blood-brain barrier. Within 15 minutes of tumor resection, the window is still wide enough for doxorubicin, a generic anthracycline chemotherapy that normally cannot cross into the brain, to slip into the surgical margin and stay for up to 72 hours in mice, University of Manchester researchers report in Science Translational Medicine this week.

Glioblastoma is the most aggressive primary brain tumor in adults. Standard care, which combines surgery, radiation, and the oral drug temozolomide, has not meaningfully extended median survival in two decades, and the tumor recurs in nearly every patient after resection. Unlike most cancers, glioblastoma almost never metastasizes; it kills by recurring in the same place. The Manchester group's bet is that the bottleneck is delivery timing, not chemistry. The surgical act itself transiently disrupts the blood-brain barrier, and that disruption is the entry point.

The carrier they used is a deliberately unglamorous one. The team picked an established, out-of-patent liposome over newer, more elaborate nanoparticles because, in his words, "we had the richest pharmacokinetic profile from these liposomes that exists for any other type of nanoparticles." The researcher calls them "low tech" liposomes, chosen for how the body handles them, not for novelty.

The mechanism has three parts. First, surgically removing the bulk of a glioblastoma briefly opens the surrounding vasculature. Second, the researchers exploit that opening by infusing doxorubicin-loaded liposomes within 15 minutes of resection, while the barrier is still leaky. Third, the liposomes are small enough to act as trojan horses, ferrying a drug that the intact blood-brain barrier would otherwise block into the tissue where residual tumor cells live.

The result, in the mouse model, is drug at the tumor margin for up to 72 hours, a window the team describes as wide enough to do adjuvant chemotherapy work. The 15-minute dosing cutoff and the 72-hour retention are the actual technical contribution. Doxorubicin itself has been around since the 1960s; what is new is the timing.

The mouse-model caveat is load-bearing. Transient barrier disruption after brain surgery has been observed in humans, but the magnitude and duration are not identical to a mouse resection. "I think the most challenging aspect of this disease is we are going very rapidly into a surgical frontline treatment, while failing very rapidly by having recurrence," the researcher told FierceBiotech. The paper's claim is that the timing window is real. Whether it survives the leap to human operating rooms is the open question.

That is also why the off-patent choice gives a faster path to the clinic. A decades-old liposome already approved for other indications can be reformulated and put through a known toxicology profile, while a fresh nanoparticle would need all of that from scratch.